Active Safety Surveillance of the 2023–2024 COVID-19 Vaccine Formulation: Findings from VSD
Abstract Number:
1720
Submission Type:
Contributed Abstract
Contributed Abstract Type:
Poster
Participants:
Lily Wang (1), Eric Weintraub (2), Burney Kieke (3), Tat’Yana Kenigsberg (1), Kimp Walton (2), Michael McNeil (2), Jonathan Duffy (1)
Institutions:
(1) CDC, N/A, (2) CDC, United States, (3) Marshfield Clinic Research Institute, N/A
Co-Author(s):
First Author:
Presenting Author:
Abstract Text:
Real-world post-vaccine safety monitoring is crucial for detecting adverse events and maintaining public trust. This study applied Rapid Cycle Analysis (RCA) to assess 2023–2024 COVID-19 vaccines (Pfizer, Moderna, Novavax) for 14 outcomes, including ischemic stroke, GBS, and myocarditis.
VSD data from nine healthcare organizations included 2.7M doses (Sep 2023–Apr 2024). Outcomes were identified in healthcare records. RCA used a concurrent comparator design to compare adverse event rates across risk and comparison intervals. Weekly monitoring with Pocock alpha-spending controlled Type I error ensured real-time safety assessment and reduced bias.
RCA identified a GBS signal after Pfizer in ≥65 yrs (aRR: 4.45, 95% CI: 1.07–22.62) and ischemic stroke signals with Pfizer (18–64 yrs: aRR: 1.48, 95% CI: 1.04–2.11) and Moderna (≥65 yrs: aRR: 1.68, 95% CI: 1.05–2.70). No signals were found for other outcomes.
RCA enables real-time vaccine safety monitoring, addressing limits of traditional comparators. While GBS and stroke signals require further evaluation, the 2023–2024 COVID-19 vaccines show a reassuring safety profile. Ongoing monitoring remains key for public trust and safety.
Keywords:
Vaccine Safety
Post-Vaccination Surveillance
Adverse Events
Rare Events
Signal Detection|Rapid Cycle Analysis (RCA)
Sequential Analysis
Concurrent Comparator Design
Pocock Alpha-Spending
Real-Time Monitoring|Vaccine Safety Datalink (VSD)
ICD-10 Codes
Healthcare Records|Guillain-Barré Syndrome (GBS)
Ischemic Stroke, Myocarditis
Adjusted Rate Ratio (aRR)
Risk and Comparison Intervals|COVID-19 Vaccine
Pfizer
Moderna
Novavax|
Sponsors:
Government Statistics Section
Tracks:
Statistical Inference
Can this be considered for alternate subtype?
Yes
Are you interested in volunteering to serve as a session chair?
Yes
I have read and understand that JSM participants must abide by the Participant Guidelines.
Yes
I understand that JSM participants must register and pay the appropriate registration fee by June 3, 2025. The registration fee is non-refundable.
I understand
You have unsaved changes.